Kevin Whitehead is a lecturer in the Neuropharmacology team, School of Clinical and Experimental Medicine and principal investigator of the Pain Signalling Group.
Kevin has extensive experience of in vivo monitoring of neurochemistry and his current research is aimed towards an understanding the role of central neuroinflammatory processes in chronic pain. This is approached through whole animal studies for which he holds a Home Office project licence. His work has attracted funding from BBSRC and Arthritis Research Campaign as well as numerous collaborations with the pharmaceutical industry (GlaxoSmithKline, Pfizer, Organon, Parke Davis and NovoNordisk). He also leads the College Glia Special Interest Group.
He teaches pharmacology and neuroscience topics across all undergraduate degree programmes offered by the Medical School as well as other undergraduate and taught postgraduate courses across the University. Kevin has supervised five postgraduate research students towards their doctorate.
Kevin regularly speaks at schools on behalf of the national group Understanding Animal Research, presenting the facts about the use of animals for the advancement of scientific and medical research. For the last 3 years Kevin has acted as a Governor for a local Birmingham secondary school. He is a member of International Association for the Study of Pain; British Neuroscience Association; Understanding Animal Research (until 2008, Research Defence Society).
Kevin Whitehead gained a BSc in Biological Scienceat the University of Edinburgh before completing his undergraduate education as a Graduate of the Institute of Biology (Pharmacology) at NESCOT (University of Surrey). He went on to study for a PhD in Neuropharmacology in the Movement Disorders Group, King’s College London under Prof Peter Jenner. After working in Prof Phil Moore’s lab in the Pharmacology Group, King’s College London, Kevin joined the University of Birmingham in 1997 as a Research Fellow working with Prof Norman Bowery in the Department of Pharmacology. This move was made possible through funding of a proposal investigating neurochemical plasticity in the spinal cord underlying chronic inflammatory pain awarded by the Arthritis Research Campaign. The proposal (written by Kevin) utilised his unique expertise in the UK in spinal microdialysis, an in vivo neurochemical monitoring technique applied to the spinal cord by only a few laboratories world-wide.
Kevin took up a teaching post in 2001 and was appointed Lecturer in 2006. He continues his research into the pathogenesis of chronic pain, focussing currently on the contribution of neuroinflammation and glial release of immune modulators (cytokines/chemokines) in the CNS to pathological pain conditions.
Whitehead K.J., C.G.S. Smith, S-A. Delaney, S.J. Curnow, M. Salmon, J.P. Hughes, IP Chessell (2010) Dynamic regulation of spinal pro-inflammatory cytokine release in the rat in vivo following peripheral nerve injury. Brain Behav. Immun. 24, 569-576
Whitehead K.J., C.G.S. Smith, S-A. Delaney, S.J. Curnow, M. Salmon, J.P. Hughes, IP Chessell (2009)Neurone-glia signalling underlies spinal pro-inflammatory cytokine release evoked by primary afferent stimulation in the neuropathic rat.Eur. J. Pain 13 (Suppl. 1): 107.
Smith C.G.S., C.M. Taylor, W.J. Winchester, K. Lee, K.J. Whitehead (2008) Alosetron modulates central serotonergic visceral pain processing in the thalamus. 12th World Congress on Pain, Glasgow, 17-22 August, 2008.
Devall A.J., K.J. Whitehead, Richards D.A. (2008) Assessment of thalamic 5-HT levels using microdialysis in a rat model of inflammatory pain. 12th World Congress on Pain, Glasgow, 17-22 August, 2008.
Smith C.G., K.J. Whitehead (2007) GABA transporter type 1 (GAT-1) uptake inhibition reduces stimulated aspartate and glutamate release in the dorsal spinal cord in vivo via different GABAergic mechanisms. Neuropharmacology 53(8): 975-981.
Devall A.J., R. Blake, N. Langman, C.G.S. Smith, D.A. Richards, K.J. Whitehead (2007) A monolithic column-based reversed-phase liquid chromatography separation for amino acid assay in biological samples. Journal of Chromatography B 848(2): 323-328.
Langman N., C.G.S. Smith, K.J. Whitehead (2006) Selective serotonin re-uptake inhibition attenuates evoked glutamate release in the dorsal horn of the anaesthetised rat in vivo. Pharmacol. Res. 53: 149-155.
Whitehead K.J., C.G.S. Smith, B. Hoggart, S.J. Curnow and M. Salmon (2006) Primary afferent induced modulation of spinal pro-inflammatory cytokine release in the neuropathic rat in vivo. Eur. J. Pain 10 (Suppl. 1): 354. 10 (Suppl. 1): 354.